Green Tea Polyphenols Reduced Fat Deposits in High Fat-Fed Rats via erk1/2-PPARγ-Adiponectin Pathway

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Tian, Chong ^a   Ye, Xiaolei ^b   Zhang, Rui ^a   Long, Jia ^a   Ren, Weiye ^a   Ding, Shibin ^a   Liao, Dan ^a   Jin, Xin ^a   Wu, Hongmei ^b   Xu, Shunqin ^a   Ying, Chenjiang ^a,c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ADIPONECTIN; DRINKING WATER; GLUCOSE; GREEN TEA POLYPHENOL; INSULIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYPHENOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; ENZYME ACTIVATION; GENE EXPRESSION; HYPOADIPONECTINEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INTRAABDOMINAL FAT; LIPID DIET; LIPID STORAGE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADIPONECTIN; ANIMALS; BODY WEIGHT; DIET, HIGH-FAT; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; INTRA-ABDOMINAL FAT; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; POLYPHENOLS; PPAR GAMMA; PROTEIN KINASE INHIBITORS; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TEA;

RATTUS; RATTUS NORVEGICUS;

EID: 84872383272     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053796     Document Type: Article

References (66)

1. Asia Pacific Cohort Studies Collaboration, (2007) The burden of overweight and obesity in the Asia-Pacific region.Obes Rev. 8(3): 191-196.
2. Pories WJ, (2008) Bariatric surgery: risks and rewards. J Clin Endocrinol Metab 93: S89-96.
3. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, et al. (2008) Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 31: 53-65.
4. Zaveri NT, (2006) Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci 78(18): 2073-2080.
5. Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N, et al. (2006) Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 296(10): 1255-1265.
6. Wolfram S, Wang Y, Thielecke F, (2006) Anti-obesity effects of green tea: from bedside to bench. Mol Nutr Food Res 50: 176-187.
7. Bose M, Lambert JD, Ju J, Reuhl KR, Shapses SA, et al. (2008) The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J Nutr 138: 1677-1683.
8. Wolfram S, Raederstorff D, Wang Y, Teixeira SR, Elste V, et al. (2005) TEAVIGO (epigallocatechin gallate) supplementation prevents obesity in rodents by reducing adipose tissue mass. Ann Nutr Metab 49: 54-63.
9. Nagao T, Komine Y, Soga S, Meguro S, Hase T, et al. (2005) Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men. Am J Clin Nutr 81: 122-129.
10. Nagao T, Hase T, Tokimitsu I, (2007) A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. Obesity (Silver Spring) 15: 1473-1483.
11. Nagao T, Meguro S, Hase T, Otsuka K, Komikado M, et al. (2009) A catechin-rich beverage improves obesity and blood glucose control in patients with type 2 diabetes. Obesity (Silver Spring) 17: 310-317.
12. Hotta K, Funahashi T, Arita Y, Takahashi M, Matuda M, et al. (2001) Plasama concentration of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. J Clic Endocrinol Metab. 86: 1930-1935.
13. Oberthuer A, Dönmez F, Oberhäuser F, Hahn M, Hoppenz M, et al. (2012) Hypoadiponectinemia in extremely low gestational age newborns with severe hyperglycemia- a matched-paired analysis. PLoS One 7(6): e38481.
14. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, et al. (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23(1): 85-89.
15. Renaldi O, Pramono B, Sinorita H, Purnomo LB, Asdie RH, et al. (2009) Hypoadiponectinemia: a risk factor for metabolic syndrome. Acta Med Indones 41(1): 20-24.
16. Lara-Castro C, Fu Y, Chung BH, Garvey WT, (2007) Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr. Opin. Lipidol 18 (3): 263-270.
17. Diez JJ, Iglesias P, (2003) The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148(3): 293-300.
18. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, et al. (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 98(4): 2005-2010.
19. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L, (2001) Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108: 1875-1881.
20. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7(8): 941-946.
21. DeClercq V, Stringer D, Hunt R, Taylor CG, Zahradka P (2011) Adipokine Production by Adipose Tissue: A novel target for treating metabolic syndrome and its sequelae. In: Wang M (ed). Metabolic Syndrome: Underlying mechanisms and drug therapies. John Wiley & Sons, Inc.: Hoboken, NJ. 73-131.
22. Shimada M, Mochizuki K, Sakurai N, Goda T, (2007) Dietary supplementation with epigallocatechin gallate elevates levels of circulating adiponectin in non-obese type-2 diabetic Goto-Kakizaki rats. Biosci Biotechnol Biochem 71(8): 2079-2082.
23. Potenza MA, Marasciulo FL, Tarquinio M, Tiravanti E, Colantuono G, et al. (2007) EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J Physiol Endocrinol Metab 292(5): E1378-1387.
24. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, et al. (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52(7): 1655-1663.
25. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, et al. (2002) Synthetic peroxisome proliferation activated receptor γ agonist, rosiglitone, increase plasma levels of adiponectin in type 2 diabetes patients. Diabetes Care 25 (2): 376-380.
26. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, et al. (2002) Induction of adipocyte complement related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization 143 (3): 998-1 007.
27. Park KS, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Nikoulina SE, et al. (1997) PPAR-gamma gene expression is elevated in skeletal muscle of obese and type II diabetic subjects. Diabetes 46, 1230-1234.
28. Inoue M, Ohtake T, Motomura W, Takahashi N, Hosoki Y, et al. (2005) Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice.Biochem Biophys Res Commun. 336(1): 215-222.
29. Gayet C, Leray1 V, Saito M, Siliart B, Nguyen P (2007) The effects of obesity-associated insulin resistance on mRNA expression of peroxisome proliferator-activated receptor-g target genes, in dogs. British Journal of Nutrition 98: 497-503.
30. Liu LR, Lin SP, Chen CC, Chen YJ, Tai CC, et al. (2011) Serum Amyloid A Induces Lipolysis by Downregulating Perilipin Through ERK1/2 and PKA Signaling Pathways. Obesity19: 2301-2309.
31. Kaplan JM, Hake PW, Denenberg A, Nowell M, Piraino G, et al. (2010) Phosphorylation of Extracellular Signal-Regulated Kinase(ERK)-1/2 Is Associated with the Downregulation of Peroxisome Proliferator-Activated Receptor (PPAR)-γ during Polymicrobial Sepsis. MOL MED 16(11-12)491-497.
32. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK, (1997) Transcriptional Activation by Peroxisome Proliferator-activated Receptor g Is Inhibited by Phosphorylation at a Consensus Mitogen-activated Protein Kinase Site. J Bio Chem 272(8): 5128-5132.
33. Hosooka T, Noguchi T, Kotani K, Nakamura T, Sakaue H, et al. (2008) Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-γ phosphorylation. Nature Medicine 14: 188-193.
34. Serisier S, Leray V, Poudroux W, Magot P, Ouguerram K, et al. (2008) Effects of green tea on insulin sensitivity, lipid profile and expression of PPARa and PPARg and their target genes in obese dogs.British Journal of Nutrition. 99: 1208-1216.
35. Li Y, Ying C, Zuo X, Yi H, Yi W, et al. (2009) Green tea polyphenols down-regulate caveolin-1 expression via ERK1/2 and p38MAPK in endothelial cells. J Nutr. Biochem 20(12): 1021-1027.
36. Ying CJ, Xu JW, Ikeda K, Takahashi K, Nara Y, et al. (2003) Tea polyphenols regulate nicotinamide adenine dinucleotide phosphate oxidase subunit expression and ameliorate angiotensin II-induced hyperpermeability in endothelial cells. Hypertens Res 26(10): 823-828.
37. Matsuzawa Y, (2010) Adiponectin: a key player in obesity related disorders.Curr Pharm Des. 16(17): 1896-1901.
38. Buechler C, Wanninger J, Neumeier M, (2011) Adiponectin, a key adipokine in obesity related liver diseases.World J Gastroenterol. 17(23): 2801-2811.
39. Yatagaia T, Nagasaka S, Taniguchib A, Fukushimac M, Nakamuraa T, et al. (2003) Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 52(10): 1274-1278.
40. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, et al. (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86(5): 1930-1935.
41. Milan G, Granzotto M, Scarda A, Calcagno A, Pagano C, et al. (2002) Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss.Obes Res. 10(11): 1095-1103.
42. Panagopoulou P, Stamna E, Tsolkas G, Galli-Tsinopoulou A, Pavlitou-Tsiontsi E, et al. (2009) Adiponectin gene polymorphisms in obese Greek youth. Pediatr Endocrinol Metab 22(10): 955-959.
43. González-Sánchez JL, Zabena CA, Martínez-Larrad MT, Fernández-Pérez C, Pérez-Barba M, et al. (2005) An SNP in the adiponectin gene is associated with decreased serum adiponectin levels and risk for impaired glucose tolerance.Obes Res. 13(5): 807-812.
44. Dastani Z, Hivert MF, Timpson N, Perry JR, Yuan X, et al. (2012) Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals.PLoS Genet. 2012 8(3): e1002607.
45. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, et al. (2004) Adiponectin acts in the brain to decrease body weight.Nat Med. 10(5): 524-529.
46. Barnea M, Shamay A, Stark AH, Madar Z, (2006) A high-fat diet has a tissue-specific effect on adiponectin and related enzyme expression.Obesity. 14(12): 2145-2153.
47. Yamane T, Kobayashi-Hattori K, Oishi Y, (2011) A high-fat diet reduces ceramide synthesis by decreasing adiponectin levels and decreases lipid content by modulating HMG-CoA reductase and CPT-1 mRNA expression in the skin.Mol Nutr Food. Res55Suppl 2: S186-192.
48. Kasim-Karakas SE, Tsodikov A, Singh U, Jialal I, (2006) Responses of inflammatory markers to a low-fat, high-carbohydrate diet: effects of energy intake. Am J Clin Nutr 83(4): 774-779.
49. Qi L, Rimm E, Liu S, Rifai N, Hu FB, (2005) Dietary glycemic index, glycemic load, cereal fiber, and plasma adiponectin concentration in diabetic men.Diabetes Care. 28(5): 1022-1028.
50. Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, et al. (2003) Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin.Diabetes. 52(2): 268-276.
51. Escrivá F, Gavete ML, Fermín Y, Pérez C, Gallardo N, et al. (2007) Effect of age and moderate food restriction on insulin sensitivity in Wistar rats: role of adiposity.J Endocrinol. 194(1): 131-141.
52. Kriketos AD, Gan SK, Poynten AM, Furler SM, Chisholm DJ, et al. (2004) Exercise increases adiponectin levels and insulin sensitivity in humans. Diabetes Care 27(2): 629-630.
53. Zeng Q, Fu L, Takekoshi K, Kawakami Y, Isobe K, (2007) Effects of short-term exercise on adiponectin and adiponectin receptor levels in rats. J Atheroscler Thromb 14(5): 261-265.
54. Hsu CH, Tsai TH, Kao YH, Hwang KC, Tseng TY, et al. (2008) Effect of green tea extract on obese women: A randomized, double-blind, placebo-controlled clinical trial. Clin Nutr 27(3): 363-370.
55. Sharabi Y, Oron-Herman M, Kamari Y, Avni I, Peleg E, et al. (2007) Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model. Am J Hypertens 20(2): 206-210.
56. Yamamoto Y, Hirose H, Miyashita K, Nishikai K, Saito I, et al. (2002) PPAR gamma 2 gene Pro12Ala polymorphism may influence serum level of an adipocyte-derived protein, adiponectin, in the Japanese population. Metabolism 51(11): 1407-1409.
57. Kursawe R, Narayan D, Cali1 A M.G, Shaw M, Pierpont B, et al (2010) Downregulation of ADIPOQ and PPARγ2 Gene Expression in Subcutaneous Adipose Tissue of Obese Adolescents With Hepatic Steatosis.Obesity. 18(10): 1911-1917.
58. Catalano1 PM, Nizielski SE, Shao J, Preston L, Qiao L, et al (2002) Downregulated IRS-1 and PPARγ in obese women with gestational diabetes: relationship to FFA during pregnancy.AJP- Endo. 282(3): E522-533.
59. Choi JH, Banks AS, Estall JL, Kajimura S, Bostrom P, et al. (2010) Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466(7305): 451-456.
60. Ohshima T, Koga H, Shimotohno K, (2004) Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. J Biol Chem 279(28): 29551-29557.
61. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, et al. (2005) Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54(12): 3442-3452.
62. Rangwala SM, Rhoades B, Shapiro JS, Rich AS, Kim JK, et al. (2003) Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev Cell 5(4): 657-663.
63. Burgermeister E, Seger R, (2007) MAPK Kinases as Nucleo-Cytoplasmic Shuttles for PPARγ. Cell Cycle 6(13): 1539-1548.
64. Gual P, Le Marchand-Brustel Y. Tanti JF, (2005) Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87: 99-109.
65. Burns KA, Vanden Heuvel JP, (2007) Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta 1771(8): 952-960.
66. Hosooka T, Noguchi T, Kotani K, Nakamura T, Sakaue H, et al. (2008) Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-gamma phosphorylation. Nat Med 14(2): 188-193.